Fig. 3From: Pan-cancer assessment of antineoplastic therapy-induced interstitial lung disease in patients receiving subsequent therapy immediately following immune checkpoint blockade therapyCumulative incidence function for the risk of developing docetaxel-induced interstitial lung disease in propensity score-matched patients with non-small cell lung cancer at the post-immune checkpoint inhibitor (ICI) or ICI-naïve settingBack to article page